4 recruiting, 2 withdrawn, 1 completed, 1 terminated. 4 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Withdrawn 2, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Refractory Hematologic Malignancy: new trials by email Literature Review of Refractory Hematologic Malignancy trials Research Report on Refractory Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning Internet-Based Intervention, Best Practice, Telephone-Based Intervention - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 400 | 2025-02-18 | 2026-08-17 |
| Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Recruiting | St. Jude Children's Research Hospital | 500 | 2023-02-08 | 2026-06-17 | |
| International Leukemia Target Board Advice - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Recruiting | Princess Maxima Center for Pediatric Oncology | 600 | 2022-12-31 | 2026-01-09 | |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. Tazemetostat, Tafasitamab, Lenalidomide - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Phase 1 / Phase 2 | Withdrawn | Epizyme, Inc. | 2021-12-22 | 2023-08-15 | |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) Emavusertib, Ibrutinib - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Curis, Inc. | 152 | 2017-12-28 | 2026-10-06 |
Hematologic Neoplasms (8) · Hodgkin Disease (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Leukemia, Hairy Cell (2) · Lymphoma, Non-Hodgkin (2) · Mastocytosis, Systemic (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia (1) · Blast Crisis (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Death (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Neoplasms by Site (8) · Neoplasms (6) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (4) · Bone Marrow Diseases (3) · Chronic Disease (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Leukemia, Myeloid (3)
Dexamethasone (2) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1) · Acetaminophen (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Bortezomib (1) · CA-4948 (1) · CTLA-4 Antigen (1) · Calcium Dobesilate (1) · Capecitabine (1) · Carboplatin (1) · Celecoxib (1)
City of Hope Medical Center (2) · Curis, Inc. (1) · Epizyme, Inc. (1) · Fred Hutchinson Cancer Center (1) · OHSU Knight Cancer Institute (1) · Princess Maxima Center for Pediatric Oncology (1) · St. Jude Children's Research Hospital (1)
United States (6) · Spain (2) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Sweden (1) · United Kingdom (1)
Aimee Talleur, MD (1) · Ibrahim Aldoss, MD (1) · Ibrahim T Aldoss (1) · Lara Davis, MD (1) · Megan J Shen, PhD (1) · Michel Zwaan, Prof. dr. (1) · Monique den Boer, Prof. dr. (1)
P30CA033572 (1), R37CA246703 (1)